News

Atlantic Healthcare starts pivotal Phase 3 trial of Alicaforsen to treat Inflammatory Bowel Disease Pouchitis

February 11, 2016

Study of fast-tracked and orphan designated alicaforsen is the largest ever in pouchitis, and aims to confirm efficacy in antibiotic refractory patients

Atlantic Healthcare plc, an international specialty pharma company focusing on gastrointestinal disorders, is pleased to announce that patient recruitment has commenced for a Phase 3 trial of its wholly-owned product alicaforsen enema to treat Inflammatory Bowel Disease (IBD) pouchitis. There are currently no approved drugs for pouchitis and this trial will be the largest ever conducted for the indication. Atlantic is recruiting 138 patients at 40 trial centres across the United States, Canada, Europe and Israel. Results are expected to be reported in H2 2017.

The trial is a randomised, double-blind, placebo-controlled, pivotal, Phase 3 safety and efficacy study of alicaforsen enema in patients with active, chronic, antibiotic refractory pouchitis. Patients will receive either 240mg alicaforsen enema or placebo, self-administered daily for six weeks. The protocol, including the primary endpoints, is agreed with the FDA, EMA, and Health Canada.

Read the full article on reuters.com here.

Are there any restrictions on the form of investment instrument?
Read FAQs

Investment Team

Meet the team

We’re pretty sparing with our email comms, but when there are interesting and relevant things happening it’s great to share. If you’d like to receive updates and hear more about what is happening with ACF Investors and the portfolio then please sign up here.

Website by James Dowen Web Designer Web Developer Web design london